Pain and Visual Outcome in Intravitreal Bevacizumab Injection
Status:
Completed
Trial end date:
2016-08-30
Target enrollment:
Participant gender:
Summary
In this double blind clinical trial, 1000 patients suffering from diabetic macular edema,
age-related macular degeneration, neovascularization due to proliferative diabetic
retinopathy and cystoid macular edema secondary to retinal vascular occlusions are included.
Those with the history of Ocular pain prior to the procedure, any contraindication for
Intravitreal Bevacizumab Injection (IVI), history of any kind of anterior segment conditions
that could affect pain sensation, history of using systemic analgesic or sedative
medications, history of previous eye surgery other than for cataract, glaucoma, uveitis and
bullous keratopathy and poor cooperation in using the visual analogue scale (VAS) are
excluded from the study. Before starting the treatment all patients undergo complete
ophthalmic exam , best-corrected visual acuity (BCVA) checking and macular thickness
measurements using optical coherence tomography (OCT). Patients are randomly assigned to each
group .Each participant receive one injection in one eye in this study. Pain is measured by
subjective grading on a Visual Analog Scale (VAS) immediately after IVI. BCVA and OCT would
be checked again at month one.